Market closedNon-fractional

Organogenesis/ORGO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Organogenesis

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Ticker

ORGO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Canton, United States

Employees

862

Organogenesis Metrics

BasicAdvanced
$370M
Market cap
65.74
P/E ratio
$0.04
EPS
1.60
Beta
-
Dividend rate
$370M
1.6
2.744
2.232
34.676
41.801
7.09%
2.28%
2.15%
65.745
0.842
1.33
1.57
53.86
-5.62%
-58.86%
4.73%
-50.99%

What the Analysts think about Organogenesis

Analyst Ratings

Majority rating from 3 analysts.
Buy

Organogenesis Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1.91% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$110M
10.34%
Net income
-$2.1M
320.00%
Profit margin
-1.91%
282.00%

Organogenesis Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.00%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.04
$0.02
-
-$0.02
-
Expected
$0.03
$0.01
$0.01
-$0.03
-$0.01
Surprise
60.00%
300.00%
-
-25.00%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Organogenesis stock?

Organogenesis (ORGO) has a market cap of $370M as of July 06, 2024.

What is the P/E ratio for Organogenesis stock?

The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 65.74 as of July 06, 2024.

Does Organogenesis stock pay dividends?

No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Organogenesis dividend payment date?

Organogenesis (ORGO) stock does not pay dividends to its shareholders.

What is the beta indicator for Organogenesis?

Organogenesis (ORGO) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Organogenesis stock

Buy or sell Organogenesis stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing